Destiny Pharma plc is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
Destiny Pharma’s Vision is of an expanding range of anti-microbial drug products which operate within existing antibiotic markets but due to their unique features, open significant, new markets that are closed to traditional antibiotics due the existence or threat of antibiotic resistance.
Its proprietary, anti-microbial drug platform, the XF Drugs Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response.
Further company information can be obtained here.
Please click here for the names and brief biographical details for the directors together with a description of their responsibilities.
Please click here for information on the Audit Committee, Remuneration Committee and Nomination Committee together with the membership of those committees.
Destiny Pharma plc is incorporated in England and Wales and the UK is the Company’s main country of operation. Details of the Company’s registered office can be found at the bottom of this page.
The Company’s Articles of Association can be downloaded here.
Shares in Destiny Pharma plc are not traded on any exchanges or trading platforms other than the AIM market.
Please click here for details of the number of securities in issue, the number of securities held as treasury shares and, insofar as the Company is aware, the percentage of securities that is not in public hands together with the identity and percentage holdings of significant shareholders.
Please click here for access to the Company’s annual and interim reports.
Please click here to access the notifications made by the Company.
The admission document can be downloaded here.
Please click here to access the Company’s Corporate Governance page.
The Company is subject to the UK City Code on Takeovers and Mergers (the City Code) issued and administered by the Panel on Takeovers and Mergers (the Takeover Panel).
Please click here for information on the Company’s advisers, including contact details.